A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Afatinib (Primary) ; Nimotuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
- 02 Jun 2015 Status changed from recruiting to completed, according to results presented at ASCO 2015.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.